TOP2A and breast carcinoma: As proof-of-principle that target expression could be linked to chemotherapy response, we tested whether transcripts of TOP2A were associated with pCR in a relatively large (GSE21094, n = 278, n = 56 pCR, n = 222 RD) cohort of breast cancer patients treated with a neoadjuvant chemotherapy regimen that contained an anthracycline (TFAC; paclitaxel [T], 5-FU [F], adriamycin [A] and cyclophosphamide[C]).